Key Takeaways
10x Genomics (NASDAQ: TXG), a leader in single-cell and spatial biology, has made a significant strategic move with its acquisition of Proteintech Genomics, announced today, June 9, 2026. This acquisition is a clear signal of TXG's intent to deepen its footprint in the burgeoning proteomics market, specifically targeting the complex realm of intracellular protein detection. While the company has faced recent revenue headwinds and a premium valuation, this integration of Proteintech Genomics' specialized assays, particularly its MultiPro Immune Profiling Cocktail, could be a pivotal step in solidifying 10x Genomics' multiomic leadership and unlocking new avenues for growth in advanced biological research.
The life science technology sector is highly competitive, and companies like 10x Genomics must constantly innovate to maintain their edge. This acquisition, coming on the heels of the Q1 2026 launch of the Atera spatial biology platform and the 2025 acquisition of Scale Biosciences, demonstrates a concerted effort by CEO Serge Saxonov and his team to broaden the company's technological capabilities. Integrating Proteintech Genomics' expertise, which includes highly multiplexed proteomic assays compatible with 10x's Chromium Single Cell Gene Expression Flex assay, positions TXG to offer researchers a more comprehensive view of cellular biology, combining gene expression with an unprecedented resolution of protein data. This strategic expansion into intracellular proteomics is crucial for advancing discoveries in fields like oncology and immunology, where understanding protein function within cells is paramount.
The core value proposition of Proteintech Genomics lies in its advanced capabilities for detecting intracellular proteins, a significant challenge in single-cell analysis that has historically remained out of reach for many platforms. Prior to this acquisition, 10x Genomics' VP of Biology, Dr. Peter Smibert, had already lauded Proteintech Genomics' MultiPro Immune Profiling Cocktail as a "game changer" for unlocking protein detection throughout the entire cell—surface, cytoplasm, and nucleus—when used with 10x's Chromium Single Cell Gene Expression Flex assay. This pre-existing synergy highlights a natural fit, suggesting that the integration will be less about building from scratch and more about accelerating an already promising collaboration.
Proteintech Genomics' MultiPro Human Discovery Panel, for instance, offers 346 antibodies against 325 distinct proteins, with two-thirds of these targets being intracellular. This extensive coverage, combined with its reported cost-effectiveness at less than half the price of competing products, makes advanced single-cell multiomics more accessible and scalable. For 10x Genomics, this means not only expanding the depth of data researchers can obtain from its Chromium platform but also potentially attracting a broader customer base by lowering the barrier to entry for comprehensive multiomic analysis. The ability to simultaneously profile the whole transcriptome and hundreds of proteins, including transcription factors and phospho-epitopes, represents a substantial leap forward in phenotypic characterization of single cells at massive scale.
This acquisition is not just about adding a new product; it's about completing the multiomic picture. While 10x Genomics has excelled in single-cell gene expression and spatial biology with platforms like Chromium and the newly launched Atera, proteomics has been an area ripe for deeper integration. By bringing Proteintech Genomics in-house, TXG gains proprietary antibody technology and expertise that directly addresses a critical unmet need in the market. This move allows 10x Genomics to offer a more unified and powerful solution, potentially increasing the stickiness of its ecosystem and driving higher consumables revenue as researchers adopt these enhanced multiomic workflows.
From a financial perspective, the immediate details of the acquisition were not disclosed, but the strategic rationale points to long-term revenue growth potential. 10x Genomics reported Q1 2026 revenue of $150.8 million, a 3% decrease year-over-year, though excluding $16.8 million in one-time license and royalty revenue from Q1 2025, revenue actually increased by 9%. The company is maintaining its full-year 2026 revenue guidance of $600 million to $625 million, which represents 0% to 4% growth over full-year 2025, excluding non-recurring patent litigation settlements. This acquisition, while not immediately impacting current guidance, is designed to fuel future growth beyond these modest projections.
The company's balance sheet remains solid, ending Q1 2026 with $539.8 million in cash, cash equivalents, and marketable securities, an increase of $112.9 million from March 31, 2025. This strong cash position provides ample flexibility for strategic acquisitions like Proteintech Genomics and continued investment in R&D. While 10x Genomics is currently unprofitable, reporting an EPS of negative $0.10 in Q1 2026 (an improvement from negative $0.28 in Q1 2025), the focus is on scaling operations and achieving long-term profitability. The company's adjusted operating margin improved to 3.7% in Q1 2026, up 9 percentage points year-on-year, indicating progress in expense management.
However, TXG's valuation remains a point of contention for some analysts. Trading at $29.18 as of June 8, 2026, with a market cap of $3.70 billion, the stock has seen a significant pullback from its 52-week high of $35.65. StockStory noted a forward price-to-sales ratio of 6.4x, suggesting a premium for a company still expected to lose money. Wall Street analysts have a consensus one-year price target of $25.77, implying a potential downside from current levels. This acquisition, if it successfully drives adoption and expands the market, could help justify the valuation by accelerating the path to sustainable profitability and robust revenue growth beyond the current guidance.
The competitive landscape in single-cell and spatial biology is intense, featuring both established giants and nimble startups. 10x Genomics faces competition from companies like Illumina (NASDAQ: ILMN), which acquired Fluent BioSciences in July 2024 to strengthen its single-cell offerings, and Bio-Rad Laboratories (NYSE: BIO). In spatial genomics, competitors include Bio-Techne and Bruker Spatial Biology (formerly NanoString Technologies), with its GeoMx Digital Spatial Profiler. The acquisition of Proteintech Genomics directly addresses a key area where 10x Genomics can differentiate itself further: comprehensive multiomic analysis that includes deep proteomic insights.
10x Genomics has historically dominated the single-cell landscape with its Chromium platform, but competitors are constantly seeking niches. The company's strategy has involved both organic innovation, such as the launch of Atera in April 2026, and strategic acquisitions. The 2025 acquisition of Scale Biosciences, valued at $30 million upfront plus potential milestones, brought in combinatorial indexing and quantum barcoding technologies, enhancing throughput and cost-effectiveness for single-cell sequencing. This latest acquisition of Proteintech Genomics complements the Scale Biosciences deal by expanding the types of data that can be efficiently collected, moving beyond just DNA/RNA to include a more complete protein profile.
The company has also been proactive in its market strategy, adjusting pricing for its single-cell systems in 2024 to encourage broader adoption and aiming for the biopharma sector to contribute 50% of its revenue. By integrating Proteintech Genomics' offerings, 10x Genomics can present a more compelling solution to biopharmaceutical companies, who are increasingly seeking multiomic approaches for drug discovery and development. This enhanced capability could help TXG capture a larger share of the high-value biopharma market, which demands the most comprehensive and high-resolution biological insights.
Investing in 10x Genomics carries both significant opportunities and notable risks. The primary opportunity lies in the company's ability to continue innovating and expanding its integrated multiomic platforms. The acquisition of Proteintech Genomics is a clear step in this direction, promising to unlock deeper biological insights and broaden the addressable market for single-cell and spatial analysis. If the integration is successful and the MultiPro assays gain widespread adoption, it could significantly boost consumables revenue and strengthen TXG's ecosystem. The company's strong cash position of $539.8 million provides a buffer for continued R&D and strategic growth initiatives.
However, several risks warrant careful consideration. First, the life science tools market is highly sensitive to research funding cycles and economic conditions. While 10x Genomics has shown resilience, ongoing research funding uncertainty and pressure on instrument pricing could cap revenue progress and squeeze margins. Second, competition remains fierce, with larger players like Illumina and innovative startups constantly vying for market share. While the Proteintech Genomics acquisition strengthens TXG's moat, competitors will undoubtedly respond with their own advancements. Third, execution risk is inherent in any acquisition; successfully integrating new technologies, teams, and product lines requires careful management to realize the intended synergies.
Furthermore, 10x Genomics' current valuation, with a forward price-to-sales ratio of 6.4x and expectations of continued losses in the near term, means that the market is pricing in substantial future growth. Any missteps in product launches, market adoption, or financial performance could lead to significant share price volatility. For example, shares traded down 5.4% to $21.20 immediately after its Q1 2026 earnings report, despite beating analyst EPS estimates, indicating investor sensitivity to growth narratives. The company's ability to convert its technological leadership into consistent, profitable revenue growth will be key to justifying its premium valuation and delivering long-term shareholder value.
The acquisition of Proteintech Genomics by 10x Genomics represents a strategically sound move to enhance its multiomic capabilities and reinforce its leadership in single-cell and spatial biology. By integrating advanced intracellular protein detection, TXG is poised to offer a more comprehensive and compelling solution to researchers, potentially driving future revenue growth and expanding its market reach. While the company faces the challenge of executing this integration and demonstrating a clear path to profitability, its strong balance sheet and commitment to innovation suggest a long-term bullish outlook for those willing to tolerate near-term volatility. Investors should closely monitor the adoption rates of the new Proteintech Genomics offerings and how they contribute to TXG's overall revenue trajectory and margin expansion in the coming quarters.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
